DiaMedica Therapeutics Inc.
DMAC
$3.77
-$0.08-2.08%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 8.05M | 7.62M | 7.85M | 7.83M | 8.32M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 29.08M | 26.68M | 24.11M | 22.38M | 21.49M |
Operating Income | -29.08M | -26.68M | -24.11M | -22.38M | -21.49M |
Income Before Tax | -26.97M | -24.41M | -21.66M | -19.86M | -19.22M |
Income Tax Expenses | 29.00K | 30.00K | 43.00K | 43.00K | 43.00K |
Earnings from Continuing Operations | -27.00 | -24.44 | -21.71 | -19.90 | -19.26 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -27.00M | -24.44M | -21.71M | -19.90M | -19.26M |
EBIT | -29.08M | -26.68M | -24.11M | -22.38M | -21.49M |
EBITDA | -29.04M | -26.64M | -24.07M | -22.35M | -21.46M |
EPS Basic | -0.65 | -0.60 | -0.55 | -0.52 | -0.55 |
Normalized Basic EPS | -0.40 | -0.38 | -0.34 | -0.33 | -0.35 |
EPS Diluted | -0.65 | -0.60 | -0.55 | -0.52 | -0.55 |
Normalized Diluted EPS | -0.40 | -0.38 | -0.34 | -0.33 | -0.35 |
Average Basic Shares Outstanding | 166.47M | 161.58M | 156.79M | 151.99M | 141.23M |
Average Diluted Shares Outstanding | 166.47M | 161.58M | 156.79M | 151.99M | 141.23M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |